Emerging Role of the Tumor Microenvironment in the Development of Metastasis, Drug Resistance, and Molecular Targeted Strategies A Commentary.

It is gradually becoming clear that cancer development represents a systems-level process that is controlled by dynamic and reciprocal interactions between the tumor microenvironment (TME) and malignant cells. The TME does not act as a passive scaffold but active regulation of tumor initiation, growth, metastatic dissemination, immune evasion and therapeutic resistance in terms of coordinated metabolic, signaling and immunological networks. Adaptive metabolic reprogramming and phenotypic plasticity in both cancer and stromal compartments were found in microenvironmental stressors like hypoxia, nutrient deprivation, and extracellular acidosis. The adaptations maintain invasive, cancer stem cell persistence, immune suppression and survival upon therapeutic pressure. Crosstalk between cells metabolism, exosome-based communication, and extracellular matrix reorganization all determine ecosystem-level resilience disrupting traditional cancer therapies. Within the framework of this commentary, we generalize emerging evidence that places the TME at a hub of metastasis and drug resistance, and we focus on metabolic plasticity, stromal re-programming and immune-metabolic competition. Based on the integrative multi-omics framework by Mir et al., we expand on the way genomics, transcriptomics, proteomics, metabolomics, and spatial profiling are redefining precision oncology by solving intratumoral heterogeneity and determining ecosystem-wide vulnerabilities. Lastly, we emphasize the possibilities of translational multi-omics-informed targeting of metabolic and stromal dependencies to break tumor ecosystem resilience and resulting clinical responses to be more durable. Importantly, such therapeutic concepts should be interpreted within the context of the intrinsic biological complexity of the tumor ecosystem, in which metabolic interventions may have divergent and cell-type-specific effects on malignant, stromal, and immune compartments, necessitating careful translational consideration.